Heart Rate Variability and Cognitive Impairment in Parkinson’s Disease
Objective: To evaluate the association between the heart rate variability (HRV) and cognitive impairment in PD patients. Background: Emerging evidence suggests an association between cognitive…Prevalence of orthostatic hypotension and postprandial hypotension in neurodegenerative diseases with synucleinopathy: a systematic review and meta-analysis
Objective: This study aimed to evaluate the prevalence of orthostatic hypotension (OH) and postprandial hypotension (PPH) in patients with Parkinson's disease (PD), multiple system atrophy…Instrumental evaluation of sleep disturbance and autonomic nervous system dysfunction in idiopathic Parkinson’s disease
Objective: The aim of the study was the instrumental evaluation of occurrence and intensity of autonomic and sleep disturbances in patients with idiopathic PD. Background:…Transient orthostatic blood pressure changes in Parkinson’s Disease: impact on falls, syncope and orthostatic intolerance
Objective: To assess the prevalence of transient orthostatic blood pressure (BP) changes and their influence on falls, syncope and orthostatic symptoms in Parkinson's disease (PD).…Predictors of Orthostatic Hypotension in Patients with Parkinson’s Disease
Objective: To investigate factors that may affect blood pressure in patients with PD (Parkinson’s disease). Background: PD affects the autonomic nervous system, potentially leading to…Changes in Supine Blood Pressure with Long Term Use of Droxidopa
Objective: To determine the long-term effects of droxidopa use on supine blood pressure (BP) in patients with neurogenic orthostatic hypotension (nOH). Background: nOH is a…A Phase 2 Study of the Efficacy, Durability and Safety of Ampreloxetine (TD-9855), a Norepinephrine Reuptake Inhibitor, Given Once-daily to Treat Neurogenic Orthostatic Hypotension (nOH) in Subjects with Synucleinopathies
Objective: To assess the efficacy and durability using validated symptom questionnaire OHQ, and safety of ampreloxetine, given once-daily to treat neurogenic orthostatic hypotension (nOH) in…A Phase 2 Dose Escalation Study of Ampreloxetine (TD-9855), a Norepinephrine Reuptake Inhibitor, Given Once-Daily to Treat Neurogenic Orthostatic Hypotension (nOH) in Subjects with Synucleinopathies
Objective: To assess the acute effects of ampreloxetine on the pressor response, improvement of symptoms and safety in a daily, single, escalating doses. Background: nOH…Population Pharmacokinetics and Pharmacodynamics of Ampreloxetine (TD-9855) in Patients with Neurogenic Orthostatic Hypotension (nOH)
Objective: To characterize the Phase 2 pharmacokinetics (PK) and pharmacodynamics (PD) of ampreloxetine in patients with nOH and provide dosing recommendations for special populations in…Differences in correlation with cardiac sympathetic denervation between depression and anhedonia in drug naïve Parkinson disease patients
Objective: To compare the correlation with some assessments of DAT scan and myocardial MIBG scintigraphy between depression and anhedonia in drug naive Parkinson's Disease (PD)…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- 9
- Next Page »